Loading organization details...
Loading organization details...
Source: IRS e-Filed Form 990 (from the IRS e-File system), Tax Year 2024
Total Revenue
▼$1.5M
Program Spending
97%
of total expenses go to program services
Total Contributions
$124.6K
Total Expenses
▼$1.5M
Total Assets
$837.1K
Total Liabilities
▼$562.6K
Net Assets
$274.4K
Officer Compensation
→$46.7K
Other Salaries
$542.5K
Investment Income
$0
Fundraising
▼N/A
Source: USAspending.gov · Searched by organization name
Total Federal Funding
$69.9M
Awards Found
23
| Awarding Agency | Description | Amount | Fiscal Year | Period |
|---|---|---|---|---|
| Department of Health and Human Services | HEALTH CENTER CLUSTER | $30.1M | FY2002 | Sep 2002 – Feb 2027 |
| Department of Health and Human Services | HEALTH CENTER CLUSTER | $26.5M | FY2002 | Sep 2002 – Feb 2020 |
| Department of Health and Human Services | AMERICAN RESCUE PLAN ACT FUNDING FOR HEALTH CENTERS | $3.7M | FY2021 | Apr 2021 – Mar 2023 |
| Department of Health and Human Services | INTESTINAL LENGTHENING VIA DISTRACTION ENTEROGENESIS FOR THE TREATMENT OF SHORT BOWEL SYNDROME - PROJECT SUMMARY SHORT BOWEL SYNDROME (SBS) IS A RARE, CHRONIC, AND DEVASTATING MALABSORPTION CONDITION WHERE PATIENTS ARE UNABLE TO ABSORB ENOUGH NUTRIENTS NATURALLY TO SUSTAIN LIFE. THIS CONDITION IS DUE TO THE LOSS OF THE MAJORITY OF THEIR SMALL INTESTINE FROM A MASSIVE SURGICAL RESECTION NECESSITATED BY CERTAIN DISEASES THAT DESTROY THE SMALL INTESTINE. IN THE PEDIATRIC PATIENT POPULATION, THE MOST COMMON DISEASES THAT LEAD TO SBS ARE NECROTIZING ENTEROCOLITIS, MIDGUT VOLVULUS, AND INTESTINAL ATRESIA. IN THE ADULT POPULATION, DISEASES INCLUDE CROHN’S, CANCER, INTESTINAL ISCHEMIA, AND TRAUMA. THESE CONDITIONS ALL RESULT IN THE NEED FOR A MASSIVE RESECTION OF THE SMALL INTESTINE LEAVING THE PATIENT WITHOUT ENOUGH FUNCTIONAL SMALL INTESTINE TO ABSORB NUTRIENTS NATURALLY. CURRENT CHRONIC THERAPIES FOR SBS INCLUDE, PARENTERAL NUTRITION, EXPENSIVE DAILY MEDICATION AND INTESTINAL SURGERY, WHICH COME AT A STAGGERING AVERAGE 5-YEAR COST OF $1.6M PER PATIENT. IT IS ESTIMATED THAT THE FIRST YEAR OF TREATMENT FOR A PEDIATRIC SBS PATIENT IS IN EXCESS OF $500,000. COMPLICATIONS FROM DAILY PARENTERAL NUTRITION INCLUDE LIVER FAILURE AND CENTRAL LINE INFECTIONS (SEPSIS). MORTALITY RATES AS HIGH AS 30% BY AGE 5 HAVE BEEN REPORTED AND NONE OF THE CURRENTLY AVAILABLE TREATMENTS FOR SBS RESTORE NATURAL ABSORPTION OF NUTRIENTS. OVER THE LAST DECADE, INTESTINAL LENGTHENING VIA DISTRACTION ENTEROGENESIS HAS EMERGED AS A POTENTIAL RESTORATIVE TREATMENT OPTION FOR PATIENTS WITH SHORT BOWEL SYNDROME. PRECLINICAL RESEARCH HAS SHOWN THAT MECHANICAL DISTRACTION DEVICES CAN STIMULATE THE GROWTH OF HEALTHY SMALL INTESTINE TISSUE IN MULTIPLE ANIMAL MODELS. LITERATURE HAS SHOWN THAT FOR EVERY ADDITIONAL 1% OF EXPECTED SMALL BOWEL A CHILD POSSESSES, THE ODDS OF WEANING FROM PARENTERAL SUPPORT INCREASES BY 3% (BELZA ET AL, 2019). THE GOAL OF THIS PROJECT IS TO MOVE THIS EMERGING TECHNOLOGY FROM THE LAB TO THE BEDSIDE BY COMPLETING AN FDA REQUESTED PRE-CLINICAL STUDY, RECEIVING IDE APPROVAL, AND CONDUCTING A FIRST-IN-HUMAN CLINICAL TRIAL. THE PHASE I PORTION OF THE PROJECT WILL PRODUCE THE PRE-CLINICAL SAFETY DATA ON THE FINAL DESIGN OF THE ECLIPSE XL1 DISTRACTION ENTEROGENESIS DEVICE REQUIRED FOR FDA IDE SUBMISSION. BASED ON FEEDBACK FROM THE FDA, PHASE II WILL PRODUCE THE FIRST IN HUMAN CLINICAL TRIAL DATA IN A STEPWISE FASHION TO ENSURE SAFETY AND PROBABLE BENEFIT. IF SUCCESSFUL, THIS NOVEL TREATMENT WILL REVOLUTIONIZE THE CARE OF SBS PATIENTS AND POTENTIALLY RETURN THEM TO ENTERAL AUTONOMY. | $2.6M | FY2021 | Jul 2021 – Aug 2028 |
| National Science Foundation | SBIR PHASE II: ENDOLUMINAL FIXATION OF A DISTRACTION ENTEROGENESIS DEVICE -THE BROADER IMPACT/COMMERCIAL POTENTIAL OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II PROJECT IS THE ADVANCEMENT OF AN INNOVATIVE THERAPY FOR SHORT BOWEL SYNDROME. COMPARED TO CURRENT NON-CURATIVE TREATMENTS THAT ARE CHRONIC AND ASSOCIATED WITH DANGEROUS COMPLICATIONS, REHOSPITALIZATION, AND HIGH MORTALITY, THE PROPOSED SOLUTION HAS THE POTENTIAL TO SUBSTANTIALLY IMPROVE OUTCOMES AND QUALITY-OF-LIFE FOR PATIENTS AND THEIR FAMILIES. THE POTENTIAL COMMERCIAL IMPACT OF THIS PROJECT IS LIKEWISE SUBSTANTIAL. TREATING SHORT BOWEL SYNDROME CURRENTLY COSTS HUNDREDS OF THOUSANDS OF DOLLARS PER PATIENT PER YEAR. ADDS MORE THAN $5 BILLION TO US HEALTHCARE EXPENDITURES ANNUALLY. THUS, THE PROPOSED CURATIVE SOLUTION CAN LEAD TO ENORMOUS SAVINGS IN DOLLARS AND IN SPECIALISTS? TIME. THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II PROJECT WILL CREATE A CURATIVE THERAPY FOR PATIENTS WITH SHORT BOWEL SYNDROME, WHICH IS CURRENTLY MANAGED WITH INTRAVENOUS NUTRITION AND LACKS EFFECTIVE TREATMENTS. THE PROPOSED SOLUTION WILL LENGTHEN THE INTESTINE, INCREASING THE ABSORPTIVE SURFACE AREA AND RESTORING THE NATURAL FUNCTION OF THE GUT, ENABLING PATIENTS TO GET SUFFICIENT NUTRITION FROM THE FOOD THEY EAT. THE PROPOSED SYSTEM COMPRISES NONDESTRUCTIVE TISSUE ANCHORS AND A SPRING THAT PUSHES AGAINST THEM TO STRETCH THE INTESTINE AND FORCE IT TO GROW. HAVING PREVIOUSLY DEVELOPED THE TISSUE ANCHORS, THIS PROJECT DEVELOPS A DELIVERY METHOD THAT WILL ALLOW THE SYSTEM TO BE IMPLANTED IN THE INTESTINE THROUGH A MINIMALLY INVASIVE PROCEDURE. FEEDBACK WILL BE GATHERED FROM PEDIATRIC GASTROENTEROLOGISTS AND SURGEONS ABOUT THE DELIVERY METHOD, AND DEVICE PERFORMANCE WILL BE MEASURED IN PRE-CLINICAL LARGE-ANIMAL STUDIES. SUCCESSFUL COMPLETION OF THE PROPOSED PROJECT WILL DEMONSTRATE INTESTINAL LENGTHENING IN VIVO, ACHIEVED VIA A MINIMALLY INVASIVE PROCEDURE, AND ESTABLISH A FOUNDATION FOR PLANNING SUBSEQUENT PRECLINICAL TESTING THAT WILL BE REQUIRED FOR REGULATORY APPROVAL TO COMMERCIALIZE THE PRODUCT. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA. | $1.5M | FY2023 | May 2023 – Apr 2027 |
| Department of Health and Human Services | FY 2021 ENDING THE HIV EPIDEMIC - PRIMARY CARE HIV PREVENTION | $821.2K | FY2023 | Sep 2023 – Aug 2025 |
| Department of Health and Human Services | HEALTH CENTER CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY (CARES) ACT FUNDING | $810.5K | FY2020 | Apr 2020 – Mar 2021 |
| Department of Health and Human Services | HEALTH CENTER INFRASTRUCTURE SUPPORT | $666.1K | FY2021 | Sep 2021 – Sep 2024 |
| Department of Health and Human Services | FISCAL YEAR 2023 CAPITAL ASSISTANCE FOR HURRICANE RESPONSE AND RECOVERY EFFORTS (CARE) | $589K | FY2023 | Sep 2023 – Aug 2026 |
| Department of Health and Human Services | ARRA - CAPITAL IMPROVEMENT PROGRAM | $509.5K | FY2009 | Jun 2009 – Jun 2011 |
| Department of Health and Human Services | AFFORDABLE CARE ACT (ACA) GRANTS FOR SCHOOL-BASED HEALTH CENTERS CAPITAL PROGRAM | $449.7K | FY2013 | Dec 2012 – Nov 2014 |
| Department of Health and Human Services | THE COMMUNITY BASED DOULA PROGRAM | $346K | FY2010 | Sep 2010 – May 2013 |
| Department of Health and Human Services | FY 2020 EXPANDING CAPACITY FOR CORONAVIRUS TESTING (ECT) | $324.8K | FY2020 | May 2020 – Apr 2021 |
| National Science Foundation | SBIR PHASE I: ENDOLUMINAL FIXATION OF A DISTRACTION ENTEROGENESIS DEVICE | $256K | FY2021 | Dec 2020 – Nov 2021 |
| Department of Health and Human Services | FY 2023 EXPANDING COVID-19 VACCINATION | $228.2K | FY2023 | Dec 2022 – Dec 2023 |
| Department of Health and Human Services | ARRA - INCREASE SERVICES TO HEALTH CENTERS | $195.2K | FY2009 | Mar 2009 – Mar 2011 |
| Department of Health and Human Services | FY 2020 CORONAVIRUS SUPPLEMENTAL FUNDING FOR HEALTH CENTERS | $65.8K | FY2020 | Mar 2020 – Jan 2021 |
| Department of Health and Human Services | FY 2023 BRIDGE ACCESS PROGRAM | $61.2K | FY2023 | Sep 2023 – Dec 2024 |
| Department of Housing and Urban Development | HOUSING COUNSELING ASSISTANCE PROGRAM | $37.9K | FY2011 | Apr 2011 – Mar 2012 |
| Department of Housing and Urban Development | HOUSING COUNSELING ASSISTANCE PROGRAM | $36.9K | FY2014 | Oct 2013 – Sep 2015 |
| Department of Housing and Urban Development | HOUSING COUNSELING | $29.8K | FY2014 | Jun 2014 – Sep 2015 |
| Department of Housing and Urban Development | HOUSING COUNSELING | $16.2K | FY2012 | Apr 2012 – Mar 2013 |
| Department of Housing and Urban Development | HOUSING COUNSELING ASSISTANCE PROGRAM | $15.5K | FY2015 | Oct 2014 – Sep 2016 |
Department of Health and Human Services
$30.1M
HEALTH CENTER CLUSTER
Department of Health and Human Services
$26.5M
HEALTH CENTER CLUSTER
Department of Health and Human Services
$3.7M
AMERICAN RESCUE PLAN ACT FUNDING FOR HEALTH CENTERS
Department of Health and Human Services
$2.6M
INTESTINAL LENGTHENING VIA DISTRACTION ENTEROGENESIS FOR THE TREATMENT OF SHORT BOWEL SYNDROME - PROJECT SUMMARY SHORT BOWEL SYNDROME (SBS) IS A RARE, CHRONIC, AND DEVASTATING MALABSORPTION CONDITION WHERE PATIENTS ARE UNABLE TO ABSORB ENOUGH NUTRIENTS NATURALLY TO SUSTAIN LIFE. THIS CONDITION IS DUE TO THE LOSS OF THE MAJORITY OF THEIR SMALL INTESTINE FROM A MASSIVE SURGICAL RESECTION NECESSITATED BY CERTAIN DISEASES THAT DESTROY THE SMALL INTESTINE. IN THE PEDIATRIC PATIENT POPULATION, THE MOST COMMON DISEASES THAT LEAD TO SBS ARE NECROTIZING ENTEROCOLITIS, MIDGUT VOLVULUS, AND INTESTINAL ATRESIA. IN THE ADULT POPULATION, DISEASES INCLUDE CROHN’S, CANCER, INTESTINAL ISCHEMIA, AND TRAUMA. THESE CONDITIONS ALL RESULT IN THE NEED FOR A MASSIVE RESECTION OF THE SMALL INTESTINE LEAVING THE PATIENT WITHOUT ENOUGH FUNCTIONAL SMALL INTESTINE TO ABSORB NUTRIENTS NATURALLY. CURRENT CHRONIC THERAPIES FOR SBS INCLUDE, PARENTERAL NUTRITION, EXPENSIVE DAILY MEDICATION AND INTESTINAL SURGERY, WHICH COME AT A STAGGERING AVERAGE 5-YEAR COST OF $1.6M PER PATIENT. IT IS ESTIMATED THAT THE FIRST YEAR OF TREATMENT FOR A PEDIATRIC SBS PATIENT IS IN EXCESS OF $500,000. COMPLICATIONS FROM DAILY PARENTERAL NUTRITION INCLUDE LIVER FAILURE AND CENTRAL LINE INFECTIONS (SEPSIS). MORTALITY RATES AS HIGH AS 30% BY AGE 5 HAVE BEEN REPORTED AND NONE OF THE CURRENTLY AVAILABLE TREATMENTS FOR SBS RESTORE NATURAL ABSORPTION OF NUTRIENTS. OVER THE LAST DECADE, INTESTINAL LENGTHENING VIA DISTRACTION ENTEROGENESIS HAS EMERGED AS A POTENTIAL RESTORATIVE TREATMENT OPTION FOR PATIENTS WITH SHORT BOWEL SYNDROME. PRECLINICAL RESEARCH HAS SHOWN THAT MECHANICAL DISTRACTION DEVICES CAN STIMULATE THE GROWTH OF HEALTHY SMALL INTESTINE TISSUE IN MULTIPLE ANIMAL MODELS. LITERATURE HAS SHOWN THAT FOR EVERY ADDITIONAL 1% OF EXPECTED SMALL BOWEL A CHILD POSSESSES, THE ODDS OF WEANING FROM PARENTERAL SUPPORT INCREASES BY 3% (BELZA ET AL, 2019). THE GOAL OF THIS PROJECT IS TO MOVE THIS EMERGING TECHNOLOGY FROM THE LAB TO THE BEDSIDE BY COMPLETING AN FDA REQUESTED PRE-CLINICAL STUDY, RECEIVING IDE APPROVAL, AND CONDUCTING A FIRST-IN-HUMAN CLINICAL TRIAL. THE PHASE I PORTION OF THE PROJECT WILL PRODUCE THE PRE-CLINICAL SAFETY DATA ON THE FINAL DESIGN OF THE ECLIPSE XL1 DISTRACTION ENTEROGENESIS DEVICE REQUIRED FOR FDA IDE SUBMISSION. BASED ON FEEDBACK FROM THE FDA, PHASE II WILL PRODUCE THE FIRST IN HUMAN CLINICAL TRIAL DATA IN A STEPWISE FASHION TO ENSURE SAFETY AND PROBABLE BENEFIT. IF SUCCESSFUL, THIS NOVEL TREATMENT WILL REVOLUTIONIZE THE CARE OF SBS PATIENTS AND POTENTIALLY RETURN THEM TO ENTERAL AUTONOMY.
National Science Foundation
$1.5M
SBIR PHASE II: ENDOLUMINAL FIXATION OF A DISTRACTION ENTEROGENESIS DEVICE -THE BROADER IMPACT/COMMERCIAL POTENTIAL OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II PROJECT IS THE ADVANCEMENT OF AN INNOVATIVE THERAPY FOR SHORT BOWEL SYNDROME. COMPARED TO CURRENT NON-CURATIVE TREATMENTS THAT ARE CHRONIC AND ASSOCIATED WITH DANGEROUS COMPLICATIONS, REHOSPITALIZATION, AND HIGH MORTALITY, THE PROPOSED SOLUTION HAS THE POTENTIAL TO SUBSTANTIALLY IMPROVE OUTCOMES AND QUALITY-OF-LIFE FOR PATIENTS AND THEIR FAMILIES. THE POTENTIAL COMMERCIAL IMPACT OF THIS PROJECT IS LIKEWISE SUBSTANTIAL. TREATING SHORT BOWEL SYNDROME CURRENTLY COSTS HUNDREDS OF THOUSANDS OF DOLLARS PER PATIENT PER YEAR. ADDS MORE THAN $5 BILLION TO US HEALTHCARE EXPENDITURES ANNUALLY. THUS, THE PROPOSED CURATIVE SOLUTION CAN LEAD TO ENORMOUS SAVINGS IN DOLLARS AND IN SPECIALISTS? TIME. THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II PROJECT WILL CREATE A CURATIVE THERAPY FOR PATIENTS WITH SHORT BOWEL SYNDROME, WHICH IS CURRENTLY MANAGED WITH INTRAVENOUS NUTRITION AND LACKS EFFECTIVE TREATMENTS. THE PROPOSED SOLUTION WILL LENGTHEN THE INTESTINE, INCREASING THE ABSORPTIVE SURFACE AREA AND RESTORING THE NATURAL FUNCTION OF THE GUT, ENABLING PATIENTS TO GET SUFFICIENT NUTRITION FROM THE FOOD THEY EAT. THE PROPOSED SYSTEM COMPRISES NONDESTRUCTIVE TISSUE ANCHORS AND A SPRING THAT PUSHES AGAINST THEM TO STRETCH THE INTESTINE AND FORCE IT TO GROW. HAVING PREVIOUSLY DEVELOPED THE TISSUE ANCHORS, THIS PROJECT DEVELOPS A DELIVERY METHOD THAT WILL ALLOW THE SYSTEM TO BE IMPLANTED IN THE INTESTINE THROUGH A MINIMALLY INVASIVE PROCEDURE. FEEDBACK WILL BE GATHERED FROM PEDIATRIC GASTROENTEROLOGISTS AND SURGEONS ABOUT THE DELIVERY METHOD, AND DEVICE PERFORMANCE WILL BE MEASURED IN PRE-CLINICAL LARGE-ANIMAL STUDIES. SUCCESSFUL COMPLETION OF THE PROPOSED PROJECT WILL DEMONSTRATE INTESTINAL LENGTHENING IN VIVO, ACHIEVED VIA A MINIMALLY INVASIVE PROCEDURE, AND ESTABLISH A FOUNDATION FOR PLANNING SUBSEQUENT PRECLINICAL TESTING THAT WILL BE REQUIRED FOR REGULATORY APPROVAL TO COMMERCIALIZE THE PRODUCT. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.
Department of Health and Human Services
$821.2K
FY 2021 ENDING THE HIV EPIDEMIC - PRIMARY CARE HIV PREVENTION
Department of Health and Human Services
$810.5K
HEALTH CENTER CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY (CARES) ACT FUNDING
Department of Health and Human Services
$666.1K
HEALTH CENTER INFRASTRUCTURE SUPPORT
Department of Health and Human Services
$589K
FISCAL YEAR 2023 CAPITAL ASSISTANCE FOR HURRICANE RESPONSE AND RECOVERY EFFORTS (CARE)
Department of Health and Human Services
$509.5K
ARRA - CAPITAL IMPROVEMENT PROGRAM
Department of Health and Human Services
$449.7K
AFFORDABLE CARE ACT (ACA) GRANTS FOR SCHOOL-BASED HEALTH CENTERS CAPITAL PROGRAM
Department of Health and Human Services
$346K
THE COMMUNITY BASED DOULA PROGRAM
Department of Health and Human Services
$324.8K
FY 2020 EXPANDING CAPACITY FOR CORONAVIRUS TESTING (ECT)
National Science Foundation
$256K
SBIR PHASE I: ENDOLUMINAL FIXATION OF A DISTRACTION ENTEROGENESIS DEVICE
Department of Health and Human Services
$228.2K
FY 2023 EXPANDING COVID-19 VACCINATION
Department of Health and Human Services
$195.2K
ARRA - INCREASE SERVICES TO HEALTH CENTERS
Department of Health and Human Services
$65.8K
FY 2020 CORONAVIRUS SUPPLEMENTAL FUNDING FOR HEALTH CENTERS
Department of Health and Human Services
$61.2K
FY 2023 BRIDGE ACCESS PROGRAM
Department of Housing and Urban Development
$37.9K
HOUSING COUNSELING ASSISTANCE PROGRAM
Department of Housing and Urban Development
$36.9K
HOUSING COUNSELING ASSISTANCE PROGRAM
Department of Housing and Urban Development
$29.8K
HOUSING COUNSELING
Department of Housing and Urban Development
$16.2K
HOUSING COUNSELING
Department of Housing and Urban Development
$15.5K
HOUSING COUNSELING ASSISTANCE PROGRAM
Source: Federal Audit Clearinghouse (fac.gov)
No federal single audit records found for this organization.
Single audits are required for entities expending $750,000+ in federal awards annually.
Tax Year 2024 · Source: IRS e-Filed Form 990
Individuals serving as officers, directors, or trustees of the organization.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other |
|---|
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: PC
990-N (e-Postcard) Filing History
This organization files simplified Form 990-N (annual gross receipts ≤ $50,000).
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2024IRS e-File | $1.5M | $124.6K | $1.5M | $837.1K | $274.4K |
| 2023 | $1.3M | $130.6K | $1.3M | $845.6K | $226.2K |
| 2022 | $1.2M | $61.1K | $1.1M | $845K | $186K |
| 2021 | $1.2M | $36.9K |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
| Tax Year | Form Type | Source | Documents |
|---|---|---|---|
| 2024 | 990 | IRS e-File | PDF not yet published by IRSView Filing → |
| 2023 | 990 | DataIRS e-File | |
| 2022 | 990 | DataIRS e-File |
Financial data: IRS e-Filed Form 990 (Tax Year 2024)
Leadership & compensation: IRS e-Filed Form 990, Part VII (Tax Year 2024)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File
Tax-deductibility: IRS Publication 78
| Total |
|---|
| Gary Mcreynolds | President | 20 | $62.3K | $0 | $0 | $62.3K |
| Karla Gerner | Chairman Of The Board | 5 | $0 | $0 | $0 | $0 |
| Eric Heatherly | Secretary | 5 | $0 | $0 | $0 | $0 |
| Sharon Weston | Officer | 5 | $0 | $0 | $0 | $0 |
| Jim Snyder | Officer | 5 | $0 | $0 | $0 | $0 |
| Carlos Turner | Officer | 5 | $0 | $0 | $0 | $0 |
| Ron Revish | Officer | 5 | $0 | $0 | $0 | $0 |
Gary Mcreynolds
President
$62.3K
Hrs/Wk
20
Compensation
$62.3K
Related Orgs
$0
Other
$0
Karla Gerner
Chairman Of The Board
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Eric Heatherly
Secretary
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Sharon Weston
Officer
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Jim Snyder
Officer
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Carlos Turner
Officer
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Ron Revish
Officer
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
| $993.1K |
| $778.5K |
| $83K |
| 2020 | $898.7K | $27.6K | $961K | $247.4K | -$105.9K |
| 2019 | $709.7K | $44K | $776.4K | $121.9K | -$26.6K |
| 2018 | $675.6K | $66.8K | $673.6K | $121.7K | $37.9K |
| 2017 | $680.8K | $83.5K | $597.4K | $125.3K | $35.9K |
| 2016 | $533.6K | $37.1K | $572.4K | $39.8K | -$47.6K |
| 2015 | $320.2K | $76.9K | $329.7K | $36.2K | -$8,745 |
| 2021 | 990 | Data |
| 2020 | 990 | Data |
| 2019 | 990 | Data |
| 2018 | 990 | Data |
| 2017 | 990 | Data | PDF not yet published by IRS |
| 2016 | 990 | Data |
| 2015 | 990 | Data |